Metastatic prostate cancer (MPC) includes metastases detected at diagnosis (de novo) and those occurring after diagnosis with early-stage disease (recurrent). Cancer registries collect data only on de novo MPC, providing a partial picture of the burden of MPC. We use cancer registry data to estimate the number of men living with MPC in the US including both de novo and recurrent cases.
We apply a back-calculation method to estimate MPC incidence and prevalence from US prostate cancer (PC) mortality and de novo MPC relative survival for cases diagnosed between 2000-2017 in 18 Surveillance, Epidemiology, and End Results registries. We hold overall PC mortality and MPC survival constant for future prevalence projections.
On January 1, 2018, we estimated 120,400 US men living with MPC (45% de novo, 55% recurrent). The age-adjusted prevalence in 2018 for Black men was over double that of White men (137.1 vs. 62.2 per 100,000 men). By 2030, 192,500 men are expected to be living with MPC, with the increase being driven by population growth projections.
The number of men living with MPC in the US exceeds 100,000 and represents a small fraction of the >3 million men living with a prior diagnosis of PC.
Relatively similar fractions of de novo and recurrent MPC among prevalent cases highlight opportunities for early detection and management of localized disease in reducing the MPC burden. Changes in diagnostic technologies could lead to greater growth in MPC cases in the US than projected.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2023 Jan 30 [Epub ahead of print]
Theresa P Devasia, Angela B Mariotto, Yaw A Nyame, Ruth Etzioni
National Cancer Institute, Bethesda, MD, United States., National Cancer Institute, Bethesda, Maryland, United States., 1984, Seattle, United States., Fred Hutchinson Cancer Research Center, Seattle, WA, United States.